Case Reports in Neurology

Published: October 2011

Open Access Gateway

Dual Therapy with Cidofovir and Mirtazapine for Progressive Multifocal Leukoencephalopathy in a Sarcoidosis Patient

Park J.H.a · Ryoo S.a · Noh H.J.a · Seo J.M.b · Kang H.H.a · Shin J.S.a · Seo S.W.a · Na D.L.a

Author affiliations

Departments of aNeurology and bRadiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Corresponding Author

Sang Won Seo, MD

Department of Neurology, Samsung Medical CenterSungkyunkwan University School of Medicine

50 Ilwon-dong, Kangnam-gu, Seoul 135-710 (Korea)

Tel. +82 2 3410 1233, E-Mail sangwonseo@empal.com

Related Articles for ""

Case Rep Neurol 2011;3:258–262

Abstract

Background: Progressive multifocal leukoencephalopathy (PML) is a demyelinating central nervous system disease caused by JC virus (JCV) reactivation in immunocompromised patients. The disease course of PML is often progressive, fatal and at present, there are few reports on successful treatment outcomes. Case Report: A 45-year-old man with systemic sarcoidosis presented with rapidly progressive dementia and right hemiparesis. The patient was diagnosed with PML as confirmed via brain biopsy and JCV PCR. With a combination treatment of cidofovir and mirtazapine, there was significant improvement of neurological symptoms without measurable functional deficit. Conclusion: This case suggests that dual therapy with cidofovir and mirtazapine might be an effective treatment option in PML patients with sarcoidosis.

© 2011 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Published: October 2011

Accepted: September 27, 2011
Published online: October 14, 2011
Issue release date: September – December

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0


eISSN: 1662-680X (Online)

For additional information: https://www.karger.com/CRN


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP